Composition and method for treating connective tissue damage by transmucosal administration
AssigneeArthroDynamic Technologies, Animal Health Division, Inc.
InventorsFrank D. Marcum, John William Seanor
Life of this patent
Estimating the term…
Loading patent…
AssigneeArthroDynamic Technologies, Animal Health Division, Inc.
InventorsFrank D. Marcum, John William Seanor
Estimating the term…
The present invention provides a composition, and a method of use thereof for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.
A composition for treating connective tissue damage in a mammal comprising a therapeutically effective amount of:
A composition for treating connective tissue damage in a mammal and in a formulation adapted for transmucosal administration, said composition consisting essentially of a therapeutically effective amount of:
A method for treating connective tissue damages in a mammal comprising transmucosally administering to a mammal in need thereof, a therapeutically effective amount of a composition comprising chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan, in the absence of a separate analgesic agent.
A method for treating connective tissue damage in a mammal comprising transmucosally administering to a mammal in need thereof, a therapeutically effective amount of a composition consisting essentially of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan, in the absence of a separate analgesic agent.
Dependencies are inferred from the claim text.